Official websites use. Share sensitive information only on official, secure websites. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Extensive high blood pressure values were not detected. The patient recovered within a week and no further seizures occurred under anticonvulsive medication. Thus, a link between interleukin-6 and the integrity of the vasculature could be considered. The clinical consequence should be a stringent blood pressure monitoring in the ambulant setting of patients receiving TCZ.
Keywords: Tocilizumab, Posterior reversible encephalopathy syndrome, Giant cell arteritis. Giant cell arteritis GCA is the most common vasculitis in adult Caucasians affecting large and medium sized vessels leading to critical ischemia.
Headache including claudicatio masticatoria are the most frequent symptoms. Vessels of all body regions can be affected in principle, however, ophthalmic manifestations are most feared and frequent, while involvement of extra- and intracranial arteries with subsequent strokes are rare complications [ 1 ].
Tocilizumab TCZ is a humanized monoclonal antibody against the interleukin-6 receptor IL-6R , which was first approved for the treatment of rheumatoid arthritis RA [ 2 ]. The approval for GCA followed in , further indications are systemic-onset juvenile idiopathic arthritis, cytokine release syndrome and others [ 3 ].
